Financial Performance Highlights
JB Chemicals reported strong FY26 results with consolidated revenue growth of 6% to ₹4,148 crores and PAT increasing 8% to ₹709 crores. EBITDA grew 8% to ₹1,178 crores with margins expanding to 28.4%. Standalone performance showed revenue of ₹3,890 crores and net profit of ₹674 crores. The domestic formulations business outperformed the Indian Pharmaceutical Market with 11% growth, maintaining #22 ranking with 6 brands in Top 300 IPM. International business grew 2% with stable CDMO performance.
Corporate Actions & Ownership Changes
Torrent Pharmaceuticals acquired a controlling 48.8% stake through two share purchase agreements and open offer, becoming the new promoter from January 21, 2026. The board approved a scheme of amalgamation with Torrent with exchange ratio of 51 Torrent shares for every 100 JB Chemicals shares. NCLT approval was received and shareholder meetings were conducted in April 2026.
Capital Commitment & Strategic Initiatives
The company made a significant capital commitment of ₹1,098 crores for perpetual ophthalmology trademark license acquisition from Novartis Innovative Therapies AG, effective January 2027 for Indian market. R&D expenditure totaled ₹119 crores with focus on complex technologies including osmotic drug delivery systems.
Dividend & Capital Allocation
The board recommended final dividend of ₹9.30 per share and declared interim dividend of ₹12.70 per share, resulting in total dividend payout of ~₹353 crores. Total assets increased to ₹4,824 crores with significant growth in inventories and investments.
Management & Board Restructuring
Significant management changes occurred with Mr. Aman Mehta appointed as Managing Director and multiple new board appointments including Mr. Sudhir Menon, Mr. Amal Kelshikar, and Mr. Hasmukh Patel. Mr. Nikhil Chopra resigned as CEO and Mr. Narayan Saraf ceased as CFO.
Exceptional Items & Contingencies
The company recognized exceptional items of ₹27.18 crore comprising severance compensation for distribution network restructuring (₹18.73 crore) and increased gratuity liability due to new Labor Codes (₹8.45 crore). Contingent liabilities included tax matters of ₹439 crores.
Operational & ESG Performance
The company maintained 8 manufacturing facilities with global regulatory approvals. ESG performance showed 43% energy from renewable sources, 100% Zero Liquid Discharge, and 29% reduction in hazardous waste. DJSI score improved 11% to 86. CSR spending was ₹13.91 crores focused on healthcare and education.
Subsidiary Performance
Key subsidiaries performed variably: Biotech Laboratories (South Africa) reported PAT of Rand 45.64 million, LLC Unique Pharmaceutical (Russia) PAT Ruble 83.47 million, while Unique Pharmaceutical FZE (Dubai) and JBCPL Philippines reported losses.
Regulatory Compliance & Governance
The financial statements were prepared in accordance with Indian Accounting Standards and complied with SEBI regulations. The Integrated Annual Report was filed under SEBI Regulation 34 with AGM scheduled for June 17, 2026.